Wednesday, 13 Dec 2017

You are here

Adalimumab Effective in Pediatric Plaque Psoriasis

Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis.  The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.

This multicenter, multinational study enrolled 114 children ages 4 to 18 yrs with severe plaque psoriasis and randomized them to treatment with adalimumab (ADA) (0·8 mg/kg or 0·4 mg/kg subcutaneously)every other week after week 1, or oral methotrexate (MTX) once weekly (0·1–0·4 mg/kg) for 16 weeks.

A week 16  PASI75 was achieved moreso with ADA (58%) compared to MTX (32%).

Clearing or minimal psoriasis was seen with 61% of ADA and 41% of the MTX patients.

There were no unexpected toxicities or infections and 3 serious adverse events were reported, all in patients in the adalimumab 0·4 mg/kg group, and were not judged to be related to study drug.

ADA appears to be effective and safe in children with plaque psoriasis. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

2017 Update of Treat to Target Recommendations for SpA/PsA

A 2017 international committee of experts met to assess and revise its earlier 2012 recommendations regarding treating to target in patients with psoriatic arthritis (PsA) and axial peripheral spondyloarthritis (SpA). 

Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis

On Friday, December 1st, the FDA approved Lilly's drug Taltz (ixekizumab) for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Taltz, an IL-17 inhibitor, has previously been approved for plaque psoriasis where it has shown high level PASI75 and PASI100 responses.

ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis

The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content - http://acr17.rheumnow.com/category/gout-crystal/

Specific items:

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.